InflaRx N.V.

IFRX • Biotechnology

$2.22

▼ -0.01 (-0.45%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$160.49M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.02Liquidez saludable · 4.13Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 7 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.22

Change-0.45%

Shares Out72.29M

Market Cap$160.49M

52W Range0.74 - 2.95

Beta2.44

P/E-2.48

P/S0.00

P/B1.50

P/FCF-7.37

EV/Sales0.00

EV/EBITDA-7.60

Price$2.22

Change-0.45%

Shares Out72.29M

Market Cap$160.49M

52W Range0.74 - 2.95

Beta2.44

P/E-2.48

P/S0.00

P/B1.50

P/FCF-7.37

EV/Sales0.00

EV/EBITDA-7.60

EV/FCF-5.55

Earnings Yield-10.09%

FCF Yield-13.57%

Dividend Yield0.00%

Gross Margin-246.78%

Oper. Margin-1645.25%

Profit Margin-1555.82%

Debt/Eq0.02

Current Ratio4.13

Quick Ratio4.13

Target$9.00

Target Upside305.41%

Target Median$9.00

Target Range9.00 - 9.00

Volume1.60M

Avg Volume1.94M

EPS Surprise0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

56/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.02Liquidez saludable · 4.13Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

IFRX

Analyst sentiment

Based on 16 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-01

Bajo

$9.00

Promedio

$9.00

Mediana

$9.00

Alto

$9.00

Resumen de la compañía

IPO: 11/7/2017

Industria: Biotechnology

P/B i: 1.50

Deuda / Patrimonio i: 0.02

Margen operativo: -164525.50%

Margen neto: -155582.08%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.02

Ratio corriente: 4.13

Ratio rápido: 4.13

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Taapken Thomas

Transacción: 03/18/2026

OTRO

Cambio

+72,000

Precio

$1.17

Presentación

03/18/2026

Tipo

OTRO

Taapken Thomas

Transacción: 03/18/2026

OTRO

Cambio

+240,000

Precio

$1.17

Presentación

03/18/2026

Tipo

OTRO

Taapken Thomas

Transacción: 03/18/2026

OTRO

Cambio

Precio

Not reported

Presentación

03/18/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Taapken Thomas	OTRO	+72,000	$1.17	03/18/2026	03/18/2026
Taapken Thomas	OTRO	+240,000	$1.17	03/18/2026	03/18/2026
Taapken Thomas	OTRO	0	Not reported	03/18/2026	03/18/2026
Riedemann Niels	OTRO	+190,500	$1.17	03/18/2026	03/18/2026
Riedemann Niels	OTRO	+635,000	$1.17	03/18/2026	03/18/2026
Riedemann Niels	OTRO	0	Not reported	03/18/2026	03/18/2026
Fulpius Nicolas	OTRO	+45,000	$1.17	03/18/2026	03/18/2026
Fulpius Nicolas	OTRO	0	Not reported	03/18/2026	03/18/2026
OCarroll Derval	OTRO	+21,000	$1.17	03/18/2026	03/18/2026
OCarroll Derval	OTRO	+70,000	$1.17	03/18/2026	03/18/2026
Gibney Anthony S	OTRO	+30,000	$1.17	03/18/2026	03/18/2026
Gibney Anthony S	OTRO	0	Not reported	03/18/2026	03/18/2026
Kubler Mark	OTRO	+30,000	$1.17	03/18/2026	03/18/2026
Kubler Mark	OTRO	0	Not reported	03/18/2026	03/18/2026

Sobre la compañía

InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Fuente - Link

Competidores

ARTV ATYR CNTB CNTX IMA KLRS MGX QNCX STRO STTK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

InflaRx Announces Participation in September Investor Conferences

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows:

GlobeNewsWire

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aR Pharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflammation and immunology (I&I) indications Virtual Capital Markets Day planned for October 8, 2026 in the morning ET Cash, cash equivalents and marketable securities totaled €158.4 million on June 30, 2026, including net proceeds from the underwritten public offering completed in May, expected to fund ongoing operations and clinical development through 2029 Jena, Germany, Aug. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.

GlobeNewsWire

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned.

GlobeNewsWire

Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)

Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 20.4% of Kamada shares are

Defense World

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessment given the recommendation of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to revoke the marketing authorization for Tavneos in the European Union, announced on June 26, 2026.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.17	-0.09	0.08
2026-03-19	-0.18	-0.17	0.01
2025-11-10	-0.16	-0.16	0
2025-08-07	-0.24	-0.24	0
2025-05-07	-0.18	-0.14	0.04
2025-03-20	-0.27	-0.09	0.18
2024-11-08	-0.27	-0.33	-0.06
2024-08-08	-0.21	-0.26	-0.05
2024-05-08	-0.24	-0.19	0.05
2024-03-21	-0.2	-0.3	-0.1
2023-11-01	-0.29	-0.14	0.15
2023-08-10	-0.36	-0.15	0.21